Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03262389 · ClinicalTrials.gov registry record · Phase 2
Comparison of F-18 FDG and C-11 Acetate PET in Multiple Myeloma
A Phase 2 study of Multiple Myeloma, sponsored by Michael C Roarke, MD.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT03262389: Completed Phase 2 study of Multiple Myeloma, sponsored by Michael C Roarke, MD.
NCT03262389 is a Phase 2 study of Multiple Myeloma that has completed, run by Michael C Roarke, MD. The registered enrollment target is 10 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03262389, a Phase 2 study of Multiple Myeloma, has completed, sponsored by Michael C Roarke, MD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
Investigators are doing this study to determine which of four imaging techniques: Fludeoxyglucose Positron Emission Tomography (18 FDG PET) computerized tomography (CT), 18 FDG PET Magnetic resonance imaging (MRI), C-11 acetate PET CT, and C-11 acetate PET MRI) is the best test for finding sites of active myeloma disease.
Primary Outcome
The number of lesions detected in the scans will be averaged for each technique. Two techniques (scans) will be tested on Day 1 and two techniques (scans) will be tested on Day 2.
Conditions Studied
Interventions
- DRUG Fludeoxyglucose PET CT
- DRUG Sodium Acetate C11 PET CT
- DRUG Fludeoxyglucose PET MRI
- DRUG Sodium Acetate C11 PET MRI
Study Locations (1)
Arizona
- Mayo Clinic in Arizona - Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2017-09-19 |
| Est. Completion | 2019-11-23 |
| Phase | Phase 2 |
What the finished NCT03262389 record still lists
NCT03262389 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 4 interventions - of which Fludeoxyglucose PET CT is the first listed.
NCT03262389 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT03262389 about?
NCT03262389 is a clinical study titled "Comparison of F-18 FDG and C-11 Acetate PET in Multiple Myeloma". Investigators are doing this study to determine which of four imaging techniques: Fludeoxyglucose Positron Emission Tomography (18 FDG PET) computerized tomography (CT), 18 FDG PET Magnetic resonance imaging (MRI), C-11 acetate PET CT, and C-11 acetate PET MRI) is the best test for finding sites of ...
What is the current status of trial NCT03262389?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2017-09-19. Estimated completion is 2019-11-23.
What conditions does trial NCT03262389 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT03262389?
The interventions under investigation include: Fludeoxyglucose PET CT (DRUG), Sodium Acetate C11 PET CT (DRUG), Fludeoxyglucose PET MRI (DRUG), Sodium Acetate C11 PET MRI (DRUG).
Who is sponsoring clinical trial NCT03262389?
This trial is sponsored by Michael C Roarke, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03262389 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03262389's enrollment target sits among peer trials
10 419th of 438 higher than 14 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
CAR T-cell Therapy in Patients With Renal Dysfunction
RECRUITING · Phase 2
-
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI